Gland Pharma Ltd Stock Price Today (NSE: GLAND)
Fundamental Score
Gland Pharma Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Gland Pharma Ltd share price today is ₹1849.50, up +0.00% on NSE/BSE as of 18 February 2026. Gland Pharma Ltd (GLAND) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹28.46K (Cr). The 52-week high for GLAND share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 36.01x, GLAND is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 7.81% and a debt-to-equity ratio of 0.03.
Gland Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Gland Pharma Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Gland Pharma Share Price: A Financial Analysis
One key trend reshaping the pharmaceutical industry is the increasing reliance on Contract Development and Manufacturing Organizations (CDMOs). This analysis delves into the financial performance of Gland Pharma Ltd, focusing on its current valuation in relation to its profitability and operational efficiency. Currently, the Gland Pharma share price stands at ₹1851.0, with a Price-to-Earnings (PE) ratio of 36.01. This valuation indicates investor expectations regarding future earnings growth.
A critical aspect of any company's financial health is its Return on Capital Employed (ROCE). Gland Pharma's ROCE of 11.89% reveals the profitability generated from its invested capital. While a positive ROCE is encouraging, its impact on the company's economic moat needs closer inspection. A consistently higher ROCE compared to its cost of capital would suggest a stronger moat, indicating Gland Pharma's ability to generate superior returns over its competitors in the long run. A lower ROCE will make the stock price more sensitive to earnings fluctuations.
Comparing Gland Pharma to its peers provides valuable context. For instance, assessing
Mankind Pharma Ltd offers insights. A subjective assessment of management quality, a notoriously difficult metric to quantify, is crucial. A strong, experienced management team can better navigate industry challenges and capitalize on opportunities, translating into superior operational performance and, ultimately, a justifiable premium on the share price. Conversely, perceived weaknesses in management could warrant caution.Further scrutiny of other key financial metrics is necessary for a comprehensive understanding. In relation to peers like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd, deeper inspection should focus on debt levels, cash flow generation, and sales growth. This analysis is part of a more comprehensive 80-parameter fundamental audit of Gland Pharma Ltd, verified by Sweta Mishra, aimed at providing a holistic view of the company's financial standing. This financial analysis is for informational purposes only and is based on publicly available data. It is observational and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Gland Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GLAND across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (28.28%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (16.36% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.03)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (24.88x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹1906.83 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (51.83%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 40.53%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Below-Average Return on Equity (7.81%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Weak Earnings Growth (-2.89% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-1.69% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Gland Pharma Ltd Financial Statements
Comprehensive financial data for Gland Pharma Ltd including income statement, balance sheet and cash flow
About GLAND (Gland Pharma Ltd)
Gland Pharma Ltd (GLAND) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹28.46K (Cr). Gland Pharma Ltd has delivered a Return on Equity (ROE) of 7.81% and a ROCE of 11.89%. The debt-to-equity ratio stands at 0.03, reflecting the company's capital structure. Investors tracking GLAND share price can monitor key metrics including P/E ratio, promoter holding of 51.83%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
GLAND Share Price: Frequently Asked Questions
What is the current share price of Gland Pharma Ltd (GLAND)?
As of 18 Feb 2026, 10:18 am IST, Gland Pharma Ltd share price is ₹1849.50. The GLAND stock has a market capitalisation of ₹28.46K (Cr) on NSE/BSE.
Is GLAND share price Overvalued or Undervalued?
GLAND share price is currently trading at a P/E ratio of 36.01x, compared to the industry average of 31.77x. Based on this relative valuation, the Gland Pharma Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of GLAND share price?
The 52-week high of GLAND share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Gland Pharma Ltd share price?
Key factors influencing GLAND share price include quarterly earnings growth (Sales Growth: 5.77%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Gland Pharma Ltd a good stock for long-term investment?
Gland Pharma Ltd shows a 5-year Profit Growth of -1.69% and an ROE of 7.81%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.03 before investing in GLAND shares.
How does Gland Pharma Ltd compare with its industry peers?
Gland Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare GLAND share price P/E of 36.01x and ROE of 7.81% against the industry averages to determine competitive standing.
What is the P/E ratio of GLAND and what does it mean?
GLAND share price has a P/E ratio of 36.01x compared to the industry average of 31.77x. Investors pay ₹36 for every ₹1 of annual earnings.
How is GLAND performing according to Bull Run's analysis?
GLAND has a Bull Run fundamental score of 45.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does GLAND belong to?
GLAND operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Gland Pharma Ltd share price.
What is Return on Equity (ROE) and why is it important for GLAND?
GLAND has an ROE of 7.81%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Gland Pharma Ltd generates profits from shareholders capital.
How is GLAND debt-to-equity ratio and what does it indicate?
GLAND has a debt-to-equity ratio of 0.03, which indicates conservative financing with low financial risk.
What is GLAND dividend yield and is it a good dividend stock?
GLAND offers a dividend yield of 1.04%, meaning you receive ₹1.04 annual dividend for every ₹100 invested in Gland Pharma Ltd shares.
How has GLAND share price grown over the past 5 years?
GLAND has achieved 5-year growth rates of: Sales Growth 16.36%, Profit Growth -1.69%, and EPS Growth -2.89%.
What is the promoter holding in GLAND and why does it matter?
Promoters hold 51.83% of GLAND shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Gland Pharma Ltd.
What is GLAND market capitalisation category?
GLAND has a market capitalisation of ₹28463 crores, placing it in the Large-cap category.
How volatile is GLAND stock?
GLAND has a beta of N/A. A beta > 1 suggests the Gland Pharma Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is GLAND operating profit margin trend?
GLAND has a 5-year average Operating Profit Margin (OPM) of 28.28%, indicating the company's operational efficiency.
How is GLAND quarterly performance?
Recent quarterly performance shows Gland Pharma Ltd YoY Sales Growth of 5.77% and YoY Profit Growth of 12.32%.
What is the institutional holding pattern in GLAND?
GLAND has FII holding of 7.90% and DII holding of 32.63%. Significant institutional holding often suggests professional confidence in the Gland Pharma Ltd stock.